文献速递瓣膜病与结构性心脏病心律失常

TAVR后新发左束支传导阻滞与中危患者不良长期结局相关:PARTNER II试验分析

New-onset left bundle branch block after transcatheter aortic valve replacement is associated with adverse long-term clinical outcomes in intermediate-risk patients: an analysis from the PARTNER II trial.
PubMed 文献 · Eur Heart J · 2019-01-01

本研究基于PARTNER II试验及S3中危注册研究,分析1179例无基线传导障碍或起搏器的中危TAVR患者,出院时新发左束支传导阻滞(LBBB)发生率为15.2%。2年随访显示,新发LBBB与全因死亡、心血管死亡、再住院、新起搏器植入及左室收缩功能恶化相关,多因素分析证实其为2年全因和心血管死亡的独立预测因子。

要点

  • 中危TAVR患者出院时新发LBBB发生率为15.2%。
  • 新发LBBB与2年全因死亡(19.3% vs 10.8%)和心血管死亡(16.2% vs 6.5%)增加相关。
  • 新发LBBB是2年全因死亡(HR 1.98)和心血管死亡(HR 2.66)的独立预测因子。

核心结论

  • 中危TAVR患者出院时持续新发LBBB与2年全因死亡、心血管死亡、再住院、新起搏器植入及左室收缩功能恶化相关。
  • 新发LBBB是多因素分析中2年全因死亡和心血管死亡的独立预测因子。

研究设计与样本

  • 基于PARTNER II试验和S3中危注册研究,共2043例TAVR患者存活至出院。
  • 排除基线传导障碍、既往永久起搏器及住院期间新起搏器后,最终分析1179例中危患者。
  • 比较出院时有无持续新发LBBB患者的2年临床结局,并进行多因素分析。

主要发现

  • 出院时新发LBBB发生率为15.2%(179/1179)。
  • 2年全因死亡率新发LBBB组19.3% vs 无LBBB组10.8%(P=0.002)。
  • 2年心血管死亡率新发LBBB组16.2% vs 无LBBB组6.5%(P<0.001)。
  • 多因素分析:新发LBBB预测2年全因死亡HR 1.98(95%CI 1.33-2.96,P<0.001),心血管死亡HR 2.66(95%CI 1.67-4.24,P<0.001)。
  • 新发LBBB还与再住院、新起搏器植入及1年和2年随访时左室收缩功能更差相关。

关键数值与推荐

  • 新发LBBB定义为出院时持续存在的左束支传导阻滞。
  • 中危患者人群来自PARTNER II试验和S3中危注册研究。

临床怎么用

  • TAVR术后应关注出院时新发LBBB,因其与不良长期结局独立相关。
  • 对新发LBBB患者需加强随访,监测死亡、心衰再住院、起搏器植入及左室功能变化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Transcatheter aortic valve replacement (TAVR) is now an established therapy for intermediate-risk surgical candidates with symptomatic, severe aortic stenosis. The clinical impact of new-onset left bundle branch block (LBBB) after TAVR remains controversial and has not been studied in intermediate-risk patients. We therefore sought to analyse outcomes associated with new LBBB in a large cohort of intermediate-risk patients treated with TAVR. METHODS AND RESULTS: A total of 2043 patients underwent TAVR in the PARTNER II trial and S3 intermediate-risk registry and survived to hospital discharge. Patients were excluded from the current analysis due to baseline conduction disturbances, pre-existing permanent pacemaker (PPM), and new PPM during the index hospitalization. Clinical outcomes at 2 years were compared between patients with and without persistent, new-onset LBBB at hospital discharge, and multivariable analysis was performed to identify predictors of mortality. Among 1179 intermediate-risk patients, new-onset LBBB at discharge occurred in 179 patients (15.2%). Patients with new LBBB were similar to those without except for more frequent diabetes and more frequent treatment with SAPIEN 3 vs. SAPIEN XT. At 2 years, new LBBB was associated with increased rates of all-cause mortality (19.3% vs. 10.8%, P = 0.002), cardiovascular mortality (16.2% vs. 6.5%, P < 0.001), rehospitalization, and new PPM implantation. By multivariable analysis, new LBBB remained an independent predictor of 2-year all-cause [hazard ratio (HR) 1.98, 95% confidence interval (95% CI) 1.33, 2.96; P < 0.001] and cardiovascular (HR 2.66 95% CI 1.67, 4.24; P < 0.001) mortality. New LBBB was also associated with worse left ventricular systolic function at 1 and 2-year follow-up. CONCLUSIONS: In a large cohort of intermediate-risk patients from the PARTNER II trial and registry, persistent, new-onset LBBB occurred in 15.2% of patients without baseline conduction disturbances or pacemaker. New LBBB was associated with adverse clinical outcomes at 2 years, including all-cause and cardiovascular mortality, rehospitalization, new pacemaker implantation, and worsened left ventricular systolic function. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov #NCT01314313 and NCT03222128.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Nazif TM, Chen S, George I, et al. New-onset left bundle branch block after transcatheter aortic valve replacement is associated with adverse long-term clinical outcomes in intermediate-risk patients: an analysis from the PARTNER II trial. Eur Heart J. 2019. PMID: 31505615. doi:10.1093/eurheartj/ehz227

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。